[Development of new software (Ver. 2.0) based on the Bayesian estimation utilized in the therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic].
We developed a new software (Ver. 2.0) based on the Bayesian estimation utilized in the therapeutic drug monitoring (TDM) of teicoplanin, a glycopeptide antibiotic, for the estimation of individual pharmacokinetic parameters. Individual pharmacokinetic parameters were calculated by a least squares methods, MULTI2 (BAYES), and a two-compartment model with population pharmacokinetic parameters in adult patients in Japan was adopted. The predicted teicoplanin concentrations in patients were similar to the observed concentrations, suggesting that the software predicts with acceptable precision. This new software is now available in clinical practice.
Niwa
Toshiro
T
Post-marketing Product Development, Astellas Pharma Inc., 3-4-7, Doshomachi, Chuo-ku, Osaka 541-8514, Japan.
Tabata
Kenji
K
Kimura
Jiro
J
Kamada
Mamoru
M
Noda
Yasuo
Y
Takagi
Akira
A
D000328:Adult; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001499:Bayes Theorem; D006801:Humans; D008962:Models, Theoretical; D012984:Software; D017334:Teicoplanin / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D017334:Teicoplanin